Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
C12orf51
REST API REST API
Homo sapiens
C12orf51 is differentially expressed in 248 experiments: 120 organism parts: cerebellum, amygdala, ... (118 more);, 165 disease states: normal, colorectal adenocarcinoma, ... (163 more);, 69 cell types 300 cell lines 28 compound treatments and 64 other conditions.
Synonyms FLJ34154, KIAA0614
Orthologs C12orf51 (2 of 3) (Danio rerio)   ENSBTAG00000008762 (Bos taurus)   ENSGALG00000014531 (Gallus gallus)   ENSBTAG00000010958 (Bos taurus)   ENSGALG00000004795 (Gallus gallus)   Gm15800 (Mus musculus)   C12orf51 (1 of 3) (Danio rerio)   F1M4W1_RAT (Rattus norvegicus)   RGD1309762 (Rattus norvegicus)   D3ZQ34_RAT (Rattus norvegicus)   c12orf51 (Xenopus laevis)   ENSCAFG00000008851 (Canis familiaris)   ENSCAFG00000008872 (Canis familiaris)   ENSBTAG00000046730 (Bos taurus)   C12orf51 (3 of 3) (Danio rerio)   (Compare orthologs)
Gene Ontology Term ligase activity, acid-amino acid ligase activity, intracellular, membrane, protein ubiquitination involved in ubiquitin-dependent protein catabolic process, protein modification process, ubiquitin-protein ligase activity, integral to membrane
InterPro Term HECT
UniProt Accession Q9Y4D8, F8VU57, F8VY39, F8VWT9, F8W0W5, F8VPX9
Search EB-eye ENSG00000173064
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (27 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
BT474
2
E-MEXP-440, E-MTAB-62
NCIH295R
1
E-MTAB-37
NA18501
1
E-GEOD-19480
NA19138
1
E-GEOD-19480
CORL105
1
E-MTAB-37
294 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-13987, ... (41 experiments)

Factor Value U/D Experiments
epithelial cell
3
E-GEOD-10797, E-GEOD-4483, E-MEXP-2034
T cell
2
E-GEOD-13987, E-GEOD-16190
fibroblast
1
2
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
2
1
E-TABM-130
BDCA1+ dendritic cell
1
1
E-TABM-34
CXCR5(hi)ICOS(hi) CD4 T cell
1
E-MEXP-750
63 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-MEXP-2280, ... (56 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-MEXP-1327
leiomyosarcoma
2
E-MTAB-62, E-MEXP-1922
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
multiple myeloma
2
E-GEOD-6691, E-MTAB-62
neuroblastoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
159 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-15205, E-GEOD-1417, E-TABM-782, E-GEOD-5824, ... (17 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-GEOD-3720, E-MEXP-1958
none
3
4
E-GEOD-1417, E-GEOD-412, E-GEOD-2803, E-MEXP-1958, E-TABM-782, ... (7 experiments)
R547
1
1
E-GEOD-15389
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
4-hydroxytamoxifen
2
1
E-MEXP-2241
22 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
82
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-4619, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-MEXP-1901

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-22148, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-6431, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-MEXP-2657, E-TABM-127, E-GEOD-20504, E-GEOD-9764, ... (9 experiments)

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-666, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246 ... (5 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.457 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM